Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Expert Opinion on Drug Delivery|August 9, 2007
Oral vaccination: where we are?Dmytro S Silin, Oksana V Lyubomska, Vichai Jirathitikal, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|November 30, 2004
Phase II placebo-controlled study of V-1 Immunitor as a therapeutic modality for treatment of HIVAldar S Bourinbaiar, Vichai Jirathitikal, Orapun Metadilogkul, et al.
Current Pharmaceutical Design|April 10, 2009
Clinical experience with therapeutic vaccines designed for patients with hepatitisDendev Batdelger, Dorjiin Dandii, Yagaanbuyant Dahgwahdorj, et al.
Expert Review of Anti-Infective Therapy|March 9, 2012
Immune approaches in tuberculosis therapy: a brief overviewAldar S Bourinbaiar, Marina V Mezentseva, Dmitry A Butov, et al.
Journal of Immune Based Therapies and Vaccines|January 20, 2011
Phase IIb randomized trial of adjunct immunotherapy in patients with first-diagnosed tuberculosis, relapsed and multi-drug-resistant (MDR) TBDmitry A Butov, Yuri N Pashkov, Anna L Stepanenko, et al.
Immunotherapy|December 25, 2010
Adjunct oral immunotherapy in patients with re-treated, multidrug-resistant or HIV-coinfected TBOlga V Arjanova, Nathalia D Prihoda, Larisa V Yurchenko, et al.
Immunotherapy|March 10, 2012
Clinical validation of sublingual formulations of Immunoxel (Dzherelo) as an adjuvant immunotherapy in treatment of TB patientsYuri V Efremenko, Olga V Arjanova, Natalia D Prihoda, et al.
Human Vaccines & Immunotherapeutics|June 21, 2013
Randomized, placebo-controlled phase II trial of heat-killed Mycobacterium vaccae (Longcom batch) formulated as an oral pill (V7)Yuri V Efremenko, Dmytro A Butov, Natalia D Prihoda, et al.
Immunotherapy|October 4, 2013
Randomized, placebo-controlled Phase II trial of heat-killed Mycobacterium vaccae (Immodulon batch) formulated as an oral pill (V7)Dmytro A Butov, Yuri V Efremenko, Natalia D Prihoda, et al.
Journal of Hepatocellular Carcinoma|April 27, 2017
Open-label Phase II clinical trial in 75 patients with advanced hepatocellular carcinoma receiving daily dose of tableted liver cancer vaccine, hepcortespenlisimut-LMarina G Tarakanovskaya, Jigjidsuren Chinburen, Purev Batchuluun, et al.
Pageof 3